Dr. Cavo on Upfront ASCT in Multiple Myeloma

Video

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for the treatment of patients with multiple myeloma.

In the study, patients were randomized to receive 4 cycles of bortezomib, melphalan, and prednisone versus high-dose melphalan and single or double ASCT as intensification therapy following induction with bortezomib, cyclophosphamide, and dexamethasone and subsequent collection of peripheral blood stem cells.

The difference between the 2 arms was statistically significant, Cavo explains. Additionally, there was an improvement in progression-free survival with ASCT. Results show that ASCT remains to be a preferred treatment regimen in newly diagnosed patients with multiple myeloma, he adds.

<<<

View more from the 2016 ASCO Annual Meeting

Related Videos
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
Casey Maguire, PhD, on Combining Viral-Like Particles and AAV
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Holly Peay, PhD, senior research scientist at RTI International
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
Holly Peay, PhD, senior research scientist at RTI International
Terence R. Flotte, MD, the vice president of ASGCT and the provost and executive deputy chancellor of UMass Chan Medical School
© 2024 MJH Life Sciences

All rights reserved.